Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Richard A, Alm"'
Autor:
Shweta Kailasan, Ravi Kant, Madeleine Noonan-Shueh, Tulasikumari Kanipakala, Grant Liao, Sergey Shulenin, Daisy W. Leung, Richard A. Alm, Rajan P. Adhikari, Gaya K. Amarasinghe, Michael L. Gross, M. Javad Aman
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Staphylococcus aureus carries an exceptional repertoire of virulence factors that aid in immune evasion. Previous single-target approaches for S. aureus-specific vaccines and monoclonal antibodies (mAbs) have failed in clinical trials due to the mult
Externí odkaz:
https://doaj.org/article/536d0a35d34246f88a85754222c857ae
Autor:
Chantal M. Morel, Richard A. Alm, Christine Årdal, Alessandra Bandera, Giacomo M. Bruno, Elena Carrara, Giorgio L. Colombo, Marlieke E. A. de Kraker, Sabiha Essack, Isabel Frost, Bruno Gonzalez-Zorn, Herman Goossens, Luca Guardabassi, Stephan Harbarth, Peter S. Jørgensen, Souha S. Kanj, Tomislav Kostyanev, Ramanan Laxminarayan, Finola Leonard, Gabriel Levy Hara, Marc Mendelson, Malgorzata Mikulska, Nico T. Mutters, Kevin Outterson, Jesus Rodriguez Baňo, Evelina Tacconelli, Luigia Scudeller, the GAP-ON€ network
Publikováno v:
Antimicrobial Resistance and Infection Control, Vol 9, Iss 1, Pp 1-14 (2020)
Abstract Objectives/purpose The costs attributable to antimicrobial resistance (AMR) remain theoretical and largely unspecified. Current figures fail to capture the full health and economic burden caused by AMR across human, animal, and environmental
Externí odkaz:
https://doaj.org/article/dc4a2198b87d4b42aacdc8e28e00a7d0
Publikováno v:
PLoS ONE, Vol 15, Iss 7, p e0236604 (2020)
The clinical pipeline continues to be insufficient to contain antimicrobial resistance, and further investment and research is needed to ensure that a robust pipeline is built to treat the WHO priority pathogens list of antibiotic-resistant bacteria.
Externí odkaz:
https://doaj.org/article/7e5fc0589a8e435e84d2751950f88f0f
Autor:
Richard A. Alm, Sushmita D. Lahiri
Publikováno v:
Antibiotics, Vol 9, Iss 7, p 418 (2020)
The number of antibacterial agents in clinical and preclinical development possessing activity against a narrow spectrum of bacterial pathogens is increasing, with many of them being nontraditional products. The key value proposition hinges on sparin
Externí odkaz:
https://doaj.org/article/5b794be49f384b06bf58ec0805bf6ff4
Autor:
Erin M. Duffy, Nadia R. Cohen, Su L. Chiang, Ed T. Buurman, Maria Uria-Nickelsen, Richard A. Alm
Publikováno v:
ACS Infectious Diseases. 7:2043-2049
The growing prevalence of antibiotic-resistant bacterial pathogens and the lack of new medicines to treat the infections they cause remain a significant global threat. In recent years, this ongoing unmet need has encouraged more research groups to fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::495d91af336e507954cc87812d30b5ef
https://doi.org/10.1021/acsinfecdis.1c00331
https://doi.org/10.1021/acsinfecdis.1c00331
Autor:
Shweta, Kailasan, Ravi, Kant, Madeleine, Noonan-Shueh, Tulasikumari, Kanipakala, Grant, Liao, Sergey, Shulenin, Daisy W, Leung, Richard A, Alm, Rajan P, Adhikari, Gaya K, Amarasinghe, Michael L, Gross, M Javad, Aman
Publikováno v:
mAbs. 14(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b2570c4cfbd20931e7026fe334d1c447
https://pubmed.ncbi.nlm.nih.gov/35730685
https://pubmed.ncbi.nlm.nih.gov/35730685
Autor:
Mark S. Butler, Valeria Gigante, Hatim Sati, Sarah Paulin, Laila Al-Sulaiman, John H. Rex, Prabhavathi Fernandes, Cesar A. Arias, Mical Paul, Guy E. Thwaites, Lloyd Czaplewski, Richard A. Alm, Christian Lienhardt, Melvin Spigelman, Lynn L. Silver, Norio Ohmagari, Roman Kozlov, Stephan Harbarth, Peter Beyer
Publikováno v:
Antimicrob Agents Chemother
There is an urgent global need for new strategies and drugs to control and treat multidrug-resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of 12 antibiotic-resistant priority pathogens and began to critica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76943be92776f3f4b8f59eb45535c2de
https://doi.org/10.1128/aac.01991-21
https://doi.org/10.1128/aac.01991-21
Autor:
Karen Gallant, Richard A. Alm
Publikováno v:
ACS Infectious Diseases. 6:1317-1322
The spread of drug-resistant bacterial pathogens has been recognized as one of the largest global threats to mankind. In order to continue to benefit from the advancement of modern medicine, new treatments, prevention, and diagnostic products are nee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::872e1f7c37be91dafc5123fea8152cdc
https://doi.org/10.1021/acsinfecdis.0c00026
https://doi.org/10.1021/acsinfecdis.0c00026
Autor:
Mark S, Butler, Valeria, Gigante, Hatim, Sati, Sarah, Paulin, Laila, Al-Sulaiman, John H, Rex, Prabhavathi, Fernandes, Cesar A, Arias, Mical, Paul, Guy E, Thwaites, Lloyd, Czaplewski, Richard A, Alm, Christian, Lienhardt, Melvin, Spigelman, Lynn L, Silver, Norio, Ohmagari, Roman, Kozlov, Stephan, Harbarth, Peter, Beyer
Publikováno v:
Antimicrob Agents Chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0b2db0b3fd1a34fe3ae36091dc172c77
https://pubmed.ncbi.nlm.nih.gov/35323013
https://pubmed.ncbi.nlm.nih.gov/35323013
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 7, p e0236604 (2020)
PLoS ONE, Vol 15, Iss 7, p e0236604 (2020)
The clinical pipeline continues to be insufficient to contain antimicrobial resistance, and further investment and research is needed to ensure that a robust pipeline is built to treat the WHO priority pathogens list of antibiotic-resistant bacteria.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393bbba7a0ebec58187ffc6bcbc586fe
http://europepmc.org/articles/PMC7386594
http://europepmc.org/articles/PMC7386594